Further subgroup analysis revealed that patients with HER2-positive patients with CNS disease who were diagnosed with breast cancer before the year 2000 had an OS of 12 months compared to 22 months for patients diagnosed after the year 2010, likely due to the advent of HER2-targeted therapy (p = 0.002). This evidence concerns the gene ERBB2 and breast cancer.